Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Halozyme Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Halozyme Therapeutics's price to sales ratio was 7.0× on Nov 11, 2026, against 6.8× a year earlier. Over the last 5 years it ranged from 5.2× to 14.3×, with a median of 7.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.0× | +0.6 |
| 2025 | Dec 31, 2025 | 6.4× | −0.1 |
| 2024 | Dec 31, 2024 | 6.4× | +0.2 |
| 2023 | Dec 29, 2023 | 6.3× | −7.0 |
| 2022 | Dec 30, 2022 | 13.3× | +1.0 |
| 2021 | Dec 31, 2021 | 12.2× | −16.7 |
| 2020 | Dec 31, 2020 | 29.0× | +16.2 |
| 2019 | Dec 31, 2019 | 12.8× | +5.3 |
| 2018 | Dec 31, 2018 | 7.5× | −9.8 |
| 2017 | Dec 29, 2017 | 17.4× | +8.6 |
| 2016 | Dec 30, 2016 | 8.7× | −7.3 |
| 2015 | Dec 31, 2015 | 16.0× | −5.0 |
| 2014 | Dec 31, 2014 | 21.1× | −5.6 |
| 2013 | Dec 31, 2013 | 26.7× | −6.3 |
| 2012 | Dec 31, 2012 | 33.0× | +15.7 |
| 2011 | Dec 30, 2011 | 17.2× | – |
See a number that looks wrong?